002800 — Sinsin Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Sinsin Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	67,129	74,008	91,926	102,586	106,388
Cost of Revenue
Gross Profit	18,514	21,774	30,301	33,408	36,218
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	71,298	75,368	86,500	96,582	99,498
Operating Profit	-4,170	-1,361	5,426	6,004	6,890
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-269	-1,747	4,047	3,995	5,141
Provision for Income Taxes
Net Income After Taxes	201	-1,449	4,355	4,646	4,811
Minority Interest
Net Income Before Extraordinary Items
Net Income	363	-1,476	4,415	4,680	4,888
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	363	-1,476	4,415	4,680	4,888
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-172	-96.5	289	308	322
Dividends per Share